Related Experiment Videos
Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised
Birgit Volgger1, Edgar Petru, Lukas Angleitner-Boubenizek
1Department Obstetrics and Gynaecology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. birgit.volgger@i-med.ac.at
Background:
The influence of two regimens of erythropoetin beta on haemoglobin level, quality of life (QoL) and side-effects in patients with gynaecological malignancies was assessed.
Patients And Methods:
A total of 119 patients during chemotherapy were randomised to either standard therapy with 10,000 IU erythropoetin beta three times a week (group A) or 20,000 IU twice a week (group B). Haemoglobin level and QoL were measured. Characteristics of the study population were analysed with descriptive statistical methods. Analysis of variance for repeated measurements was performed with haemoglobin level as dependent variable, and time and study arms as factors.
Results:
The rise in haemoglobin levels and QoL improvement were significant, without any difference between study arms. Adverse events were similar, except significantly more thromboembolic events in group B (0 vs. 8 events; p = 0.003).
Conclusion:
Our results show similar improvements in haemoglobin level and QoL, but raise the question whether less frequent dosing regimes may result in increased rates of thromboembolic events.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials: Overview
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...